Compounders Research Compare

Erasca, Inc.(ERAS)

Biotechnology · San Diego, CA

$14.30-0.42 (-2.85%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Erasca, Inc.

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

San Diego, CA

103 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jonathan E. Lim

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T20:41:20.801Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:41:20.801Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -0.95
Quote price: 14.3

FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

ERAS Earnings Yield Metrics

EARNINGS YIELD

N/A

ERAS Competitors' Earnings Yield

Erasca, Inc.

Current

Market Cap

$4.96B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Waystar Holding Corp.

Market Cap

$5.06B

Earnings Yield

2.65%

TTM Avg

2.51%

3Y Avg

1.98%

5Y Avg

1.98%

Merit Medical Systems, Inc.

Market Cap

$5.07B

Earnings Yield

2.85%

TTM Avg

2.80%

3Y Avg

2.38%

5Y Avg

2.05%

Scholar Rock Holding Corporation

Market Cap

$5.09B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Oruka Therapeutics, Inc.

Market Cap

$4.84B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mirum Pharmaceuticals, Inc.

Market Cap

$4.83B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Dianthus Therapeutics, Inc.

Market Cap

$4.78B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cogent Biosciences, Inc.

Market Cap

$5.19B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Doximity, Inc.

Market Cap

$5.20B

Earnings Yield

3.06%

TTM Avg

3.81%

3Y Avg

2.64%

5Y Avg

2.45%

Definium Therapeutics, Inc.

Market Cap

$4.73B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Erasca, Inc. (ERAS)	$4.96B	N/A	N/A	N/A	N/A
Waystar Holding Corp. (WAY)vs ›	$5.06B	2.65%	2.51%	1.98%	1.98%
Merit Medical Systems, Inc. (MMSI)vs ›	$5.07B	2.85%	2.80%	2.38%	2.05%
Scholar Rock Holding Corporation (SRRK)vs ›	$5.09B	N/A	N/A	N/A	N/A
Oruka Therapeutics, Inc. (ORKA)vs ›	$4.84B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.83B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.78B	N/A	N/A	N/A	N/A
Cogent Biosciences, Inc. (COGT)vs ›	$5.19B	N/A	N/A	N/A	N/A
Doximity, Inc. (DOCS)vs ›	$5.20B	3.06%	3.81%	2.64%	2.45%
Definium Therapeutics, Inc. (DFTX)vs ›	$4.73B	N/A	N/A	N/A	N/A

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics